Lumida
/ALGN
⌘K
Align Technology Inc

Align Technology Inc

ALGN
$150.82USD↑+0.07%+0.10 today

MARKET CAP

10.7B

P/E (TTM)

25.3x

FWD P/E

—

DAY RANGE

$149 – $154

52W RANGE

$122
$200

AI Summary

Stalk
Sell NowMedium

ALGN is in a Stage 4 decline with a clear sequence of lower highs and lower lows, and downward-sloping EMAs acting as resistance. Price is extended below the 9EMA and 20EMA, and RSI is extreme oversold without visible exhaustion. There are no active bullish patterns or mean-reversion eligibility, reinforcing a bearish medium-term posture. Short-term timing conditions favor immediate participation in further downside (Sell Now). A decisive reclaim and sustained acceptance above the 9EMA/20EMA zone would invalidate this bearish stance.

  • ↑Q4 revenue $1.048B (+5.3% YoY) with 677k clear aligner cases.
  • ↑Clear aligner sales $838M (+5.5% YoY); operating margin at 22.7%.
  • ↓North America retail sales pressured by macro uncertainty, slowing growth.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Align Technology, Inc. (NASDAQ: ALGN) is a leader in the orthodontics sector, specializing in digital orthodontics and clear aligner solutions, particularly through its flagship product, Invisalign. The company operates on a global scale, primarily through two segments: clear aligners and systems/services, which include intraoral scanning technologies. Align’s focus on innovation and digital workflows positions it well to meet the evolving demands of orthodontic treatments, amid competitive pressures and shifts in consumer behavior towards digital solutions.

Bull says

  • ↑Q4 revenue $1.048B (+5.3% YoY) with 677k clear aligner cases.
  • ↑Clear aligner sales $838M (+5.5% YoY); operating margin at 22.7%.
  • ↑Expanded buyback to $400M–$500M; 2.9M shares repurchased at $162.09.
  • ↑EMEA and APAC deliver double-digit growth via DSO partnerships.
  • ↑ClinCheck Live Plan cuts treatment planning to just 15 minutes.
  • ↑Strong earnings yield and robust liquidity underpin valuation upside.

Bear says

  • ↓North America retail sales pressured by macro uncertainty, slowing growth.
  • ↓Profitability weakened with compressed margins in the retail channel.
  • ↓Capital equipment revenue down on lower scanner ASPs.
  • ↓UK VAT ruling incurs ~$37.5M liability, straining cash flow.
  • ↓Stock volatility remains elevated, risking unpredictable share performance.
  • ↓Negative growth and revision signals point to potential earnings shortfalls.

Investment themes with ALGN

High Beta↓ -0.84%

Stocks with high volatility relative to market

AMD · DELL · MPWR

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-15-2026neutral

Transcript signals

Bull points

  • we did have a good increase you know, close to 14% growth. And we saw a good trade out. I mean, we see the same surveys and we work around the industry that you do and we know there's a reluctance because of lack of patient traffic in dental offices and ortho offices of them to commit to capital equipment.
  • we felt good about the uptake of Lumina and the excitement we see in the marketplace.
  • You have others and it's really mostly on the ortho channel. They're in, they want to go into treatment. You might be a teenager and parents bring that child in. And you know, due to some of the economics or other things that we see at that patient, at that practice that is there, that doctor because of economics puts that patient that's in their chair into wires and brackets versus maybe they might even came in asking for Invisalign.

Bear points

  • we didn't meet our sales goals for Lumina in the second quarter
  • we thought we'd sell more full systems. But what we did is our 5D plus product was upgradable to Lumina with a wand switch and the majority of our sales went to the wand side.
  • And so that's just not the same amount of revenue in that switch. And that's basically what hurt us.
Read full transcript analysis ›